Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: Comparative effects of prasugrel and ticagrelor on platelet reactivity

International Journal of Cardiology

Volumn 174, Issue 3, 2014, Pages 874-876

  Lhermusier, T ^a,b   Voisin, S ^a   Murat, G ^a   Mejean, S ^a   Garcia, C ^a,b   Bataille, V ^a   Lipinski, M J ^c   Carrie D ^a   Sie P ^a,b  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b University Hospital of Toulouse   (France)

^c WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Acute coronary syndrome; Clopidogrel; Platelet reactivity; Prasugrel; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL; TICAGRELOR; ADENOSINE; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; AGED; ANGIOCARDIOGRAPHY; AREA UNDER THE CURVE; BLEEDING; BLOOD CLOTTING PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY STENT; DRUG MEGADOSE; FEMALE; HUMAN; LETTER; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PLASMA CONCENTRATION-TIME CURVE; PLATELET REACTIVITY; PLATELET REACTIVITY INDEX; PLATELET REACTIVITY UNIT; PRIORITY JOURNAL; PROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; DRUG SUBSTITUTION; METABOLISM; MIDDLE AGED; PROCEDURES; THROMBOCYTE; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADENOSINE; AGED; BLOOD PLATELETS; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84903276353     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.04.208     Document Type: Article

References (20)

1. C.W. Hamm, J.-P. Bassand, and S. Agewall et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
2. R.S. Wright, J.L. Anderson, and C.D. Adams et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons J Am Coll Cardiol 57 2011 e215 e367
3. Task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), and W. Wijns et al. Guidelines on myocardial revascularization Eur Heart J 31 2010 2501 2555
4. L. Wallentin, R.C. Becker, and A. Budaj et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
5. S.D. Wiviott, E. Braunwald, and C.H. McCabe et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
6. L. Wallentin, C. Varenhorst, and S. James et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease Eur Heart J 29 2008 21 30
7. R.F. Storey, D.J. Angiolillo, and S.B. Patil et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy J Am Coll Cardiol 56 2010 1456 1462
8. T. Lhermusier, S. Voisin, S. Mejean, C. Garcia, P. Sié, and D. Carrié Switching patients from clopidogrel to prasugrel in acute coronary syndrome: effects of prasugrel loading dose on residual platelet reactivity J Thromb Haemost 10 2012 1946 1949
9. J.G. Diodati, J.F. Saucedo, and J.K. French et al. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients (TRIPLET): a randomized controlled trial Circ Cardiovasc Interv 6 2013 567 574
10. D. Carrié, C. Garcia, M.P. Gratacap, S. Voisin, B. Payrastre, and P. Sié Assessment of platelet response to clopidogrel through measurement of ADP-induced Akt phosphorylation J Thromb Haemost 7 2009 1411 1413
11. Y.-H. Jeong, K.P. Bliden, U.S. Tantry, and P.A. Gurbel High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low? J Thromb Haemost 10 2012 487 489
12. U.S. Tantry, L. Bonello, D. Aradi, M.J. Price, Y.-H. Jeong, and D.J. Angiolillo et al. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to ADP Associated with Ischemia and Bleeding J Am Coll Cardiol 2013 2261 2273
13. M.K. Freynhofer, V. Bruno, M. Willheim, W. Hübl, J. Wojta, and K. Huber Vasodilator-stimulated phosphoprotein-phosphorylation assay in patients on clopidogrel: does standardisation matter? Thromb Haemost 107 2012 538 544
14. P.A. Gurbel, K.P. Bliden, and K. Butler et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study Circulation 121 2010 1188 1199
15. D. Alexopoulos, I. Xanthopoulou, and V. Gkizas et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction Circ Cardiovasc Interv 5 2012 797 804
16. D. Yang, H. Chen, and M. Koupenova et al. A new role for the A2b adenosine receptor in regulating platelet function J Thromb Haemost 8 2010 817 827
17. S. Nylander, E.A. Femia, and M. Scavone et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism J Thromb Haemost 11 2013 1867 1876
18. L. Bonello, M. Laine, N. Kipson, J. Mancini, O. Helal, and J. Fromonot et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome J Am Coll Cardiol 2014 872 877
19. G. Parodi, B. Bellandi, and F. Venditti et al. Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel Am J Cardiol 109 2012 214 218
20. E.M. Antman, S.D. Wiviott, and S.A. Murphy et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel- Thrombolysis In Myocardial Infarction) analysis J Am Coll Cardiol 51 2008 2028 2033